Dr. William Williams reports

BRIACELL THERAPEUTICS ANNOUNCES PRICING OF $15 MILLION PUBLIC OFFERING

Briacell Therapeutics Corp. has priced a best-efforts public offering of 12 million units. Each unit consists of one common share (or prefinanced warrant in lieu thereof) and one warrant. Each unit is being sold to the public at a price of $1.25 per unit (inclusive of the prefinanced warrant exercise price) for gross proceeds of $15-million, before deducting placement agent fees and offering expenses. Each warrant is immediately exercisable and entitles the holder to purchase one common share at an exercise price of $1.50 per share and will expire five years from the date of issuance. The common shares (or prefinanced warrants) and warrants can only be purchased together in the offering but will be issued separately.

The offering is expected to close on July 16, 2025, subject to satisfaction of customary closing conditions. No Canadian prospectus has been or will be filed in a province or territory of Canada to qualify the securities in connection with the offering. The company is relying upon the exemption set forth in Section 602.1 of the Toronto Stock Exchange company manual, which provides that the TSX will not apply its standards to certain transactions involving eligible interlisted issuers on a recognized exchange, such as the Nasdaq Stock Market.

The company intends to use the net proceeds from the offering for working capital requirements, general corporate purposes and the advancement of business objectives.

ThinkEquity is acting as the sole placement agent for the offering.

A registration statement on Form S-1 (file No. 333-288562) relating to the securities was filed with the U.S. Securities and Exchange Commission (SEC) and became effective on July 15, 2025. This offering is being made only by means of a prospectus. Copies of the final prospectus, when available, may be obtained from ThinkEquity, 17 State St., 41st floor, New York, N.Y., 10004. The final prospectus will be filed with the SEC and will be available on the SEC's website.

About Briacell Therapeutics Corp.

Briacell is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care.

We seek Safe Harbor.